| USTUN, C., A. REITER, B. SCOTT, R. NAKAMURA, G. DAMAJ, S. KREIL, R. SHANLEY, W. HOGAN, M.A. PERALES, T. SHORE, H. BAURMANN, R. STUART, B. GRUHN, Michael DOUBEK, J. HSU, E. THOLOULI, T. GROMKE, L. GODLEY, L. PAGANO, A. GILMAN, E.M. WAGNER, T. SHWAYDER, M. BORNHAUSER, E. PAPADOPOULOS, A. BOHM, G. VERCELLOTTI, M.T. VAN LINT, Ch. SCHMID, W. RABITSCH, V. PULLARKAT, F. LEGRAND, I. YAKOUB-AGHA, W. SABER, J. BARRETT, O. HERMINE, H. HAGGLUND, W. SPERR, U. POPAT, E. ALYEA, S. DEVINE, H.J. DEEG, D. WEISDORF, C. AKIN a P. VALENT. Hematopoietic Stem-Cell Transplantation for Advanced Systemic Mastocytosis. Journal of clinical oncology. Alexandria (USA): AMER SOC CLINICAL ONCOLOGY, 2014, roč. 32, č. 29, s. 3264-3281. ISSN 0732-183X. Dostupné z: https://dx.doi.org/10.1200/JCO.2014.55.2018. |
Další formáty:
BibTeX
LaTeX
RIS
@article{1217032,
author = {Ustun, C. and Reiter, A. and Scott, B. and Nakamura, R. and Damaj, G. and Kreil, S. and Shanley, R. and Hogan, W. and Perales, M.A. and Shore, T. and Baurmann, H. and Stuart, R. and Gruhn, B. and Doubek, Michael and Hsu, J. and Tholouli, E. and Gromke, T. and Godley, L. and Pagano, L. and Gilman, A. and Wagner, E.M. and Shwayder, T. and Bornhauser, M. and Papadopoulos, E. and Bohm, A. and Vercellotti, G. and Van Lint, M.T. and Schmid, Ch. and Rabitsch, W. and Pullarkat, V. and Legrand, F. and Yakoubandagha, I. and Saber, W. and Barrett, J. and Hermine, O. and Hagglund, H. and Sperr, W. and Popat, U. and Alyea, E. and Devine, S. and Deeg, H.J. and Weisdorf, D. and Akin, C. and Valent, P.},
article_location = {Alexandria (USA)},
article_number = {29},
doi = {http://dx.doi.org/10.1200/JCO.2014.55.2018},
keywords = {Systemic Mastocytosis; fatal hematopoietic malignancy},
language = {eng},
issn = {0732-183X},
journal = {Journal of clinical oncology},
title = {Hematopoietic Stem-Cell Transplantation for Advanced Systemic Mastocytosis},
url = {http://jco.ascopubs.org/content/32/29/3264.full.pdf+html},
volume = {32},
year = {2014}
}
TY - JOUR
ID - 1217032
AU - Ustun, C. - Reiter, A. - Scott, B. - Nakamura, R. - Damaj, G. - Kreil, S. - Shanley, R. - Hogan, W. - Perales, M.A. - Shore, T. - Baurmann, H. - Stuart, R. - Gruhn, B. - Doubek, Michael - Hsu, J. - Tholouli, E. - Gromke, T. - Godley, L. - Pagano, L. - Gilman, A. - Wagner, E.M. - Shwayder, T. - Bornhauser, M. - Papadopoulos, E. - Bohm, A. - Vercellotti, G. - Van Lint, M.T. - Schmid, Ch. - Rabitsch, W. - Pullarkat, V. - Legrand, F. - Yakoub-agha, I. - Saber, W. - Barrett, J. - Hermine, O. - Hagglund, H. - Sperr, W. - Popat, U. - Alyea, E. - Devine, S. - Deeg, H.J. - Weisdorf, D. - Akin, C. - Valent, P.
PY - 2014
TI - Hematopoietic Stem-Cell Transplantation for Advanced Systemic Mastocytosis
JF - Journal of clinical oncology
VL - 32
IS - 29
SP - 3264-3281
EP - 3264-3281
PB - AMER SOC CLINICAL ONCOLOGY
SN - 0732183X
KW - Systemic Mastocytosis
KW - fatal hematopoietic malignancy
UR - http://jco.ascopubs.org/content/32/29/3264.full.pdf+html
L2 - http://jco.ascopubs.org/content/32/29/3264.full.pdf+html
N2 - Purpose Advanced systemic mastocytosis (SM), a fatal hematopoietic malignancy characterized by drug resistance, has no standard therapy. The effectiveness of allogeneic hematopoietic stem-cell transplantation (alloHCT) in SM remains unknown. Patients and Methods In a global effort to define the value of HCT in SM, 57 patients with the following subtypes of SM were evaluated: SM associated with clonal hematologic non–mast cell disorders (SM-AHNMD; n = 38), mast cell leukemia (MCL; n = 12), and aggressive SM (ASM; n = 7). Median age of patients was 46 years (range, 11 to 67 years). Donors were HLA-identical (n = 34), unrelated (n = 17), umbilical cord blood (n = 2), HLA-haploidentical (n = 1), or unknown (n = 3). Thirty-six patients received myeloablative conditioning (MAC), and 21 patients received reduced-intensity conditioning (RIC). Results Responses in SM were observed in 40 patients (70%), with complete remission in 16 patients (28%). Twelve patients (21%) had stable disease, and five patients (9%) had primary refractory disease. Overall survival (OS) at 3 years was 57% for all patients, 74% for patients with SM-AHNMD, 43% for those with ASM, and 17% for those with MCL. The strongest risk factor for poor OS was MCL. Survival was also lower in patients receiving RIC compared with MAC and in patients having progression compared with patients having stable disease or response. Conclusion AlloHCT was associated with long-term survival in patients with advanced SM. Although alloHCT may be considered as a viable and potentially curative therapeutic option for advanced SM in the meantime, given that this is a retrospective analysis with no control group, the definitive role of alloHCT will need to be determined by a prospective trial.
ER -
USTUN, C., A. REITER, B. SCOTT, R. NAKAMURA, G. DAMAJ, S. KREIL, R. SHANLEY, W. HOGAN, M.A. PERALES, T. SHORE, H. BAURMANN, R. STUART, B. GRUHN, Michael DOUBEK, J. HSU, E. THOLOULI, T. GROMKE, L. GODLEY, L. PAGANO, A. GILMAN, E.M. WAGNER, T. SHWAYDER, M. BORNHAUSER, E. PAPADOPOULOS, A. BOHM, G. VERCELLOTTI, M.T. VAN LINT, Ch. SCHMID, W. RABITSCH, V. PULLARKAT, F. LEGRAND, I. YAKOUB-AGHA, W. SABER, J. BARRETT, O. HERMINE, H. HAGGLUND, W. SPERR, U. POPAT, E. ALYEA, S. DEVINE, H.J. DEEG, D. WEISDORF, C. AKIN a P. VALENT. Hematopoietic Stem-Cell Transplantation for Advanced Systemic Mastocytosis. \textit{Journal of clinical oncology}. Alexandria (USA): AMER SOC CLINICAL ONCOLOGY, 2014, roč.~32, č.~29, s.~3264-3281. ISSN~0732-183X. Dostupné z: https://dx.doi.org/10.1200/JCO.2014.55.2018.
|
